
US Patent Application No: 2012/0189,542
Number of patents in Portfolio can not be more than 2000
Anti-CD19 Antibodies
Stats
-
Jul 26, 2012
Publication date -
Feb 16, 2012
filing date -
13/398,214
serial no -
Granted
status
Importance
Loading Importance Indicators...
Abstract
The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.
Loading the Abstract Image...
First Claim
Related Publications
Loading Related Publications...
International Classification(s)
- [Classification Symbol]
- [Patents Count]